C-Path announces formation of new task force to foster drug development for Progressive Supranuclear Palsy

NewsGuard 100/100 Score

Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), dedicated to advancing therapeutic development for Progressive Supranuclear Palsy (PSP). This initiative brings together leading organizations and experts in a concerted effort to tackle the challenges associated with PSP drug development. PSP is a brain disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood, behavior and thought.

The confirmed members of the task force include the Rainwater Charitable Foundation, CurePSP, The Association for Frontotemporal Degeneration (AFTD), Novartis, and Dr. Adam Boxer, a distinguished neurologist at the UCSF Memory and Aging Center. 

This task force aims to leverage the collective expertise of its members to foster innovation and expedite the development of new treatments for PSP. By integrating patient-level data from diverse sources through RDCA-DAP, the task force will work to identify and address the critical gaps in PSP research and development. The collaboration provides a neutral platform for stakeholders from industry, regulatory agencies, academia, and the PSP community to engage in meaningful dialogue and share data, enhancing the efficiency of therapeutic advancements for PSP.

"Progressive Supranuclear Palsy is a devastating condition with significant unmet medical needs," said Alexandre Betourne, Pharm. D., Ph.D., RDCA-DAP Executive Director and lead for this effort. "By convening this task force, we are harnessing the collective strengths and knowledge of our members to drive forward the development of effective treatments for those affected by PSP."

The task force's approach is rooted in C-Path's proven track record of fostering collaboration and accelerating drug development processes. Its focus will include establishing data management standards, identifying biomarkers, and utilizing modeling and analytics to inform regulatory science and clinical outcome assessments. This strategic effort is designed to de-risk the decision-making process in drug development and enhance the regulatory review of novel therapeutics for PSP.

As the leading nonprofit organization serving those living with Progressive Supranuclear Palsy, we're thrilled to be part of this enabling initiative. Data sharing, data access, and public-private partnerships are needed to make a difference. We're committed to supporting this endeavor and to representing the patient voice in partnership with C-Path."

Kristophe Diaz, Ph.D., Executive Director, and Chief Science Officer at CurePSP

For further information and to inquire about joining the RDCA-DAP Task Force on Progressive Supranuclear Palsy, interested parties are encouraged to contact [email protected].


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers sex differences in brain responses to low sexual desire